A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer
Clinical trial NCT03989037 · COMPLETED
Trial details
- NCT number
- NCT03989037
- Sponsor
- Shanghai Institute Of Biological Products
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-27
- Primary completion
- 2023-04-26
- Enrollment
- 580
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.